CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Amicus Therapeutics, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Amicus Therapeutics, Inc.
47 Hulfish Street
Phone: (302) 658-7581p:302 658-7581 PRINCETON, NJ  08542  United States Fax: (302) 655-5049f:302 655-5049
This company was Merged or Acquired on 4/27/2026.
This company ceased filing statements with the SEC on 5/7/2026.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202512/31/2025YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Michael G.Raab 60 3/4/2024 1/1/2004
President, Chief Executive Officer, Director Bradley L.Campbell 49 8/1/2022 5/1/2007
Chief Financial Officer Simon N.Harford 64 8/21/2023 8/21/2023
7 additional Officers and Directors records available in full report.

Business Names
Business Name
Amicus Biologics, Inc.
Amicus GT Holdings, LLC (Delaware)
Amicus Therapeutics ApS
24 additional Business Names available in full report.

General Information
Number of Employees: 511 (As of 12/31/2025)
Outstanding Shares: 314,000,712 (As of 2/12/2026)
Shareholders: 15
Stock Exchange: NASD
Federal Tax Id: 200422823
Fax Number: (302) 655-5049
Email Address: info@amicustherapeutics.com


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, May 12, 2026